OTCMKTS:JCRRF JCR Pharmaceuticals (JCRRF) Stock Price, News & Analysis → The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique Way (From Smallcaps Daily) (Ad) Free JCRRF Stock Alerts $5.22 0.00 (0.00%) (As of 05/7/2024 ET) Add Compare Share Share Today's Range$5.22▼$5.2250-Day Range$5.22▼$6.2052-Week Range$5.22▼$6.20VolumeN/AAverage Volume267 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get JCR Pharmaceuticals alerts: Email Address Ad Crypto 101 MediaIncredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About JCR Pharmaceuticals Stock (OTCMKTS:JCRRF)JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices and laboratory instruments; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a. joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.Read More JCRRF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart JCRRF Stock News HeadlinesMarch 19, 2024 | finance.yahoo.comJCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo® Technology for Neurodegenerative Disease in Research Collaboration with AlexionMarch 2, 2024 | morningstar.comJCR Pharmaceuticals Co Ltd 4552May 8, 2024 | InvestorPlace (Ad)The new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.February 29, 2024 | finance.yahoo.comJCR Pharmaceuticals Celebrates Rare Disease Day 2024 and Highlights Its Commitment to the Rare Disease CommunityFebruary 14, 2024 | finance.yahoo.comJCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2024 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage DisordersJanuary 25, 2024 | markets.businessinsider.comJCR Pharmaceuticals earnings preview: what Wall Street is expectingJanuary 25, 2024 | finance.yahoo.comJCR Pharmaceuticals to Present at the 20th Annual WORLDSymposium™ 2024December 21, 2023 | finance.yahoo.comJCR Announces Research Collaboration, Option and License Agreement with Alexion on Discovery of Oligonucleotide Therapeutics Using J-Brain Cargo® TechnologyMay 8, 2024 | InvestorPlace (Ad)The new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.December 21, 2023 | finance.yahoo.comJCR Pharmaceuticals and Takeda Pharmaceuticals Announce Discontinuation of Gene Therapy CollaborationDecember 15, 2023 | finance.yahoo.comU.S. FDA Grants Orphan Drug Designation to JR-441 for the Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)November 13, 2023 | msn.comJCR Pharmaceuticals doses first patient in MPS IIIA trialOctober 24, 2023 | markets.businessinsider.comJCR Pharmaceuticals earnings preview: what to expectSeptember 29, 2023 | finance.yahoo.comJCR Pharmaceuticals Announces 52-Week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I (MPS I)September 28, 2023 | marketwatch.comJCR Pharmaceuticals Shares Jump After It Raises Earnings GuidanceJuly 27, 2023 | markets.businessinsider.comHere's what Wall Street expects from JCR Pharmaceuticals's earnings reportMay 17, 2023 | investing.comJCR Pharmaceuticals Co Ltd (4552)May 11, 2023 | news.yahoo.comItaly's Angelini invests up to $506 million in Japan's JCR for epilepsy drugMay 11, 2023 | reuters.comItaly's Angelini invests up to $506 mln in Japan's JCR for epilepsy drugApril 3, 2023 | finance.yahoo.comJCR Pharmaceuticals Announces Research Collaboration, Option and License Agreement with Alexion to Develop a Therapy Using J-Brain CargoⓇ for Neurodegenerative DiseaseSee More Headlines Receive JCRRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for JCR Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - General Sub-IndustryN/A Current SymbolOTCMKTS:JCRRF CUSIPN/A CIKN/A Webwww.jcrpharm.co.jp Phone81 7 9732 8591FaxN/AEmployees879Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Shin Ashida (Age 81)Chairman, CEO & President Yoshihiro OtaDirector of Accounting Department & Corporate Strategy Department (Finance)Yutaka HondaSenior Corporate Officer, Executive Director of Administration Div. & Director of Human ResourcesHiroyuki FukuyaDirector of Legal Affairs Department - Administration DivisionToru Ashida (Age 56)Senior VP of Sales & Administration, Executive Director of Sales Division and Director Ryutaro MakinoDirector of Marketing Dept. & Group Manager of Product Planning - Marketing Dept. for Sales Div.Katsuya Nishino (Age 68)Executive Vice President Hiroshi Yoshimoto (Age 73)Senior Advisor Takayo EgawaCorporate Officer & Director of International Affairs OfficeMr. Hiroyuki Sonoda Ph.D. (Age 46)VP of Research & Corporate Strategy, Executive Director of Research Division and Director More ExecutivesKey CompetitorsAstraZenecaOTCMKTS:AZNCFCosmo PharmaceuticalsOTC:CMOPFCSPC Pharmaceutical GroupOTCMKTS:CSPCYDaiichi SankyoOTCMKTS:DSNKYDechra PharmaceuticalsOTCMKTS:DCHPFView All Competitors JCRRF Stock Analysis - Frequently Asked Questions Should I buy or sell JCR Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for JCR Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" JCRRF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in JCRRF, but not buy additional shares or sell existing shares. View JCRRF analyst ratings or view top-rated stocks. How have JCRRF shares performed in 2024? JCR Pharmaceuticals' stock was trading at $9.04 on January 1st, 2024. Since then, JCRRF stock has decreased by 42.3% and is now trading at $5.22. View the best growth stocks for 2024 here. Are investors shorting JCR Pharmaceuticals? JCR Pharmaceuticals saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 590,800 shares, a decline of 6.0% from the March 15th total of 628,800 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is presently ∞ days. View JCR Pharmaceuticals' Short Interest. How do I buy shares of JCR Pharmaceuticals? Shares of JCRRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:JCRRF) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorAI “wealth window” is closing June 25thParadigm PressStock-Picking AI Predicts #1 Stock of 2024Altimetry[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe #1 lithium battery stock to have on your radar in 2024!Smallcaps Daily Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding JCR Pharmaceuticals Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
